We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Online Data Retrieval Software Eases Access to Cancer Cell-Line Information

By LabMedica International staff writers
Posted on 02 Aug 2012
An online application freely available to biotech and genomics researchers allows rapid data retrieval from one of the largest and best-characterized cancer cell databases.

A paper published in the July 15, 2012, issue of the journal Cancer Research described the CellMiner software application, which was designed for use with the [US] National Cancer Institute's (Bethesda, MD, USA) NCI-60 library. More...


The NCI-60 is a set of 59 human cancer cell lines derived from diverse tissues: brain, blood and bone marrow, breast, colon, kidney, lung, ovary, prostate, and skin. Since 1992 these cell lines have been subjected to a battery of experiments including; extensive pharmacological characterization by treatment with over 100,000 chemical compounds, chromosome karyotyping, and gene expression analyses conducted with various DNA microarray platforms.

CellMiner is a web application that facilitates systems biology through the retrieval and integration of the molecular and pharmacological data sets for the NCI-60 cell lines. The tools that comprise CellMiner are available online for free (please see Related Links below). These tools provide rapid access to data from 22,379 genes catalogued in the NCI-60 library and from 20,503 previously analyzed chemical compounds, including 102 [US] Food and Drug Administration (FDA)-approved drugs.

"Previously you would have to hire a bioinformatics team to sort through all of the data, but these tools put the entire database at the fingertips of any researcher," said senior author Dr. Yves Pommier, head of the laboratory of molecular pharmacology at the National Cancer Institute. "These tools allow researchers to analyze drug responses as well as make comparisons from drug to drug and gene to gene. We are looking forward to seeing how other people are going to use this tool to look at gene coregulation, regulation of gene expression, and the relationship between gene expression and cancer."

Related Links:

National Cancer Institute
CellMiner



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.